Rentschler Biopharma SE, a global CDMO for biopharmaceuticals, including advanced therapy medicinal products (ATMPs), is constructing a new state-of-the-art buffer media station at its company headquarters in Laupheim. The new facility aims to further increase production efficiency and modernize the site.
 
The four-story buffer media station, covering 34,000 square meters, is set to be operational by 2028. The new facility will be integrated with the existing infrastructure to help offer faster and more efficient processes, as well as ergonomically designed workstations. The new building, along with all technical systems, will be designed to meet the highest quality and automation standards, with state-of-the-art equipment.
 
“This investment underscores our commitment to the long-term development of our Laupheim site, a key part of Germany’s biotechnology landscape. This expansion will strengthen our competitive position in one of the world’s fastest-growing industries. As a company with 150 years of tradition, Rentschler Biopharma has always embraced forward-looking, strategic planning, enabling us to grow sustainably as an independent family-owned company. I would like to thank all colleagues involved in the planning and execution of this significant project,” said Benedikt von Braunmühl, Chief Executive Officer of Rentschler Biopharma. 
 
The new facility will include three media tanks and six buffer tanks, providing sufficient space and capacity for the production of buffer solutions and media. Buffer and media preparation will be carried out in separate areas to ensure the highest standards of hygiene and safety. In addition, the facility will be connected to the in-house logistics system and the piping system for upstream and downstream processes.